The level of deletion 17p and bi-allelic inactivation of <i>TP53</i> has a significant impact on clinical outcome in multiple myeloma
2017 · Haematologica · 78 citations
https://doi.org/10.3324/haematol.2017.168872
C
Cody Ashby
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
185
Papers
3.6K
Citations
24
h-index
44
i10-index
Cody Ashby is an academic researcher from University of Arkansas Medical Center. The author has contributed to research in topics: Multiple Myeloma Research and Treatments & Protein Degradation and Inhibitors & Peptidase Inhibition and Analysis. The author has an h-index of 24, co-authored 158 publications.
ORCID: 0000-0002-9361-0283Papers by this author
worksLoss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?
2018 · Leukemia · 62 citations
https://doi.org/10.1038/s41375-018-0017-0
Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker
2017 · Blood Cancer Journal · 59 citations
https://doi.org/10.1038/bcj.2017.12
Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns
2020 · Blood Cancer Journal · 37 citations
https://doi.org/10.1038/s41408-020-0336-z
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
2024 · Nature Communications · 33 citations
https://doi.org/10.1038/s41467-024-44873-4
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
2024 · Blood Cancer Journal · 24 citations
https://doi.org/10.1038/s41408-024-01172-x
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat